CASSS is excited to announce that the US Food and Drug Administration (FDA) and CASSS will combine their strengths to develop this year's WCBP program. The Scientific Organizing Committee is collaborating on the current agenda, which includes identifying speakers, creating workshops, selecting roundtable discussions, and soliciting poster presentations. The program will reflect scientific input from industry, regulators, and non-profit organizations.
Image of session chairs, speakers, and panelists from WCBP 2024 Plenary Session 6 - Clearing the Fog: Particle Visibility and Regulatory Updates for Visual Inspection of Parenteral Drug Products (from left to right): Antonio
Burazer, Takeda Austria GmbH, John Shabushnig, Insight Pharma Consulting, LLC, Rukman De Silva, CDER, FDA, Felix Nikels, Boehringer Ingelheim, Atanas Koulov, Clear Solutions Laboratories AG, Maryam Mazaheri, I-MAB Biopharma
Co., Ltd., Sophia Levitskaya-Seaman, MacroGenics, Inc., Ewa Marszal, CBER, FDA, and Patricia Cash, Global Biotech Experts, LLC.
Image of panelists from WCBP 2024 Plenary Session 2 - Transforming Global Regulatory CMC Practices in an Age of Revolutionary Innovation (from left to right): Samvel Azatyan,
WHO - World Health Organization, Nino Mihokovic,
EMA - European Medicines Agency, Ingrid Markovic,
CBER, FDA, Nelio Aquino,
ANVISA, Yasuhiro Kishioka,
PMDA - Pharmaceuticals and Medical Devices Agency, and Steve Kozlowski,
CDER, FDA.
Image of a packed conference room at WCBP 2023 Opening Remarks.